VGX-1027-GIT-27-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVGX-1027Cat. No.: HY-15507CAS No.: 6501-72-0Synonyms: GIT 27分式: CHNO分量: 205.21作靶點(diǎn): Interleukin Related作通路: Immunology/Inflammation儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 56 mg/mL (2

2、72.89 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 4.8731 mL 24.3653 mL 48.7306 mL5 mM 0.9746 mL 4.8731 mL 9.7461 mL10 mM 0.4873 mL 2.4365 mL 4.8731 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 VGX-1027(GIT27)具有免疫調(diào)節(jié)活性，能降低巨噬細(xì)胞的I

3、L-1，TNF-和IL-10分泌。戶使本產(chǎn)品發(fā)表的科研獻(xiàn)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE mustansiriya medical journal. 2018 Nov.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Stosic-Grujicic S, et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid,

4、 preventsspontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multipl2. Stojanovic I, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation ofcytokine synthesis an

5、d prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immuno3. Mangano K, et al. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis inmice by the novel immunomodulatory agent VGX-1027. Eur J Pharmacol. 2008 May 31;586(1-3):313-21.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 0